Striking a balance between eradicating a malignancy and minimizing collateral damage has proven to be a persistently elusive goal. As a result, patients undergoing traditional oncologic treatment have often been plagued by side effects and tumor recurrences. Treatments such as external beam radiation or systemic chemotherapy are often not sufficiently tumor specific and the resulting collateral damage may result in significant morbidity. [1] [2] [3] [4] On the other hand, the inability to comprehensively detect and physically remove micrometastases is a limitation of surgical excision that may set the stage for early recurrence.
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Another option to consider for these patients is interventional oncology. With the use of image-guided percutaneous and catheter-based procedures, interventional oncologists can deliver therapy directly to the tissue in question. Much like surgical excision, many interventional techniques favor precision over systemic efficacy; however, a key difference between these two schools of thought is that interventional oncologists do not remove the cancerous tissue; the tumors are instead destroyed in situ. 9 Thermal ablation in particular disrupts malignant cells, causing the release of antigens and inducing the expression of proinflammatory cytokines that can go on to activate and prime the immune system to attack occult malignant cells. 10 While ablation alone may stop short of enacting a complete antitumor immune response, it may help to set the stage for other, more systemically acting immunotherapies by functioning as an in situ tumor vaccine.
necrosis or apoptosis of malignant cells thus exposing antigens that would otherwise escape detection. 9, 14, 15 Antigens unveiled by thermal destruction can be taken up by antigen presenting cells that may then go on to prime cytotoxic cells for an antitumor immune response 9, 16 (►Fig. 1). This ability of ablation to expose the antigenic components of malignant cells to the immune system has been referred to as generating an in situ cancer vaccine. 12, 16, 17 Although not the focus of this discussion, it is worth noting that many investigators have sought to capitalize on and enhance this immunogenic effect by combining forms of ablation with medical therapies such as granulocyte-macrophage colony-stimulating factor (Perothech, Rocky Hill, NJ), bacterial-derived immunostimulants, or immune checkpoint inhibitors. [18] [19] [20] [21] The current review will cover the immunological effects that have been observed when thermal ablation is used as a monotherapy.
Radio Frequency Ablation
Radio frequency ablation (RFA) utilizes applicator probes in conjunction with a grounding pad to generate a high-frequency, alternating current. Through frictional heating, this form of ablation is capable of producing temperatures in excess of 60°C, thereby causing coagulative necrosis of the nearby cells. 9 When the temperature rises above 100°C, tissue can char and the impendence to RF current increases drastically, thus limiting the effect of the ablation probe.
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Additionally, RFA's mechanism of heating with electromagnetic current is particularly susceptible to the heat-sink effect, where nearby blood vessels siphon away heat and mitigate thermal damage 23 (►Fig. 2A). and effector memory T cells exhibited an initial reduction in numbers that they attributed to surgically induced immune suppression followed by a significant rebound indicative of an activated immune response. 28 Together these results suggest that the immune response induced by RFA changes over time. Abbreviations: CA, cryoablation; DAMP, damage-associated molecular protein; DNA, deoxyribonucleic acid; HIFU, high-intensity focused ultrasound; HSP, heat shock protein; IFN-γ; interferon gamma; IL-6, interleukin 6; MWA, microwave ablation; NK, natural killer; RFA, radio frequency ablation; TNF-α, tumor necrosis factor alpha.
Significant modulations in other inflammatory markers have also been reported after RFA. In addition to its effects on T cells, Giardino et al also found that RFA was associated with a significant induction of the pro-inflammatory cytokine interleukin 6 (IL-6) and antigen presenting dendritic cells (DC). 28 Other studies have shown that RFA increases IL-6 as well as IL-1β, hepatocyte growth factor, vascular endothelial growth factor (VEGF), and tumor necrosis factor alpha (TNF-α). [29] [30] [31] [32] However, at least one group has reported that there was no effect on IL-1β or IL-6 up to 48 hours after RFA treatment of hepatic metastases. 33 One possible explanation for this outlier is that levels of these inflammatory cytokines vary over time after RFA, just as T cell populations do, but more data are necessary to make that assertion. Numerous studies have also reported on the effect that RFA has on heat shock proteins (HSP), with results showing that RFA significantly induces cellular expression of HSP70 and HSP90, as well as increasing the serum levels of HSP70. [34] [35] [36] [37] [38] [39] Concomitant decreases in nuclear expression of HSP90 suggest that RFA promotes its translocation to the cell surface.
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One group that looked specifically at the immune response in intestinal mucosa induced by RFA of the liver in rats found that after ablation, expression of CD4þ T cells, CD8 þ T cells, CD68 þ macrophages, and MAdCAM-1 all increased significantly as compared with control. Furthermore, the proinflammatory cytokines TNF-α, IL-6, and nuclear factor kappa beta (NF-κβ) also increased significantly. 40 RFA of hepatic tumors has also been shown to induce systemic inflammatory symptoms, elevating temperature, mean arterial pressure, IL-1, adrenaline, and noradrenaline up to 24 hours after the procedure. 41 Along the same lines, another study showed that RFA produced fever and increased neutrophils only in patients with metastatic liver cancer, not those with primary disease.
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Notably, the inflammatory response after RFA has been consistently reported as being less significant than what is seen after cryoablation (CA). 30 Similarly, while the in situ destruction of tumoral tissue by RFA has been shown to promote DC infiltration, loading, and maturation, it is reportedly far less efficient than in CA.
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In regard to the effects of RFA on immunosuppression, Giardino et al showed that RFA does not induce expansion or activation of regulatory T cells. 28 Other investigators have reported that RFA does not have an impact on the immunosuppressive cytokines transforming growth factor-beta (TGF-β) or IL-10. 32, 33 However, it has also been reported in lung cancer patients that RFA produces a significant reduction in circulating CD25 þ FoxP3 þ regulatory T cells that corresponds to increase in CD4þ T cells and interferon gamma (IFN-γ) secreting cells between 30 and 90 days after ablation. 46 Another group found that while RFA significantly reduced the volume of circulating regulatory T cells (T regs ), it was less profound than surgical excision.
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Several authors have studied the specificity of the antitumor immune response. In a rabbit model of VX2 hepatoma, RFA was able to generate a significant tumor-specific T cell response as well as dense T cell infiltration. 47 Clinical studies of primary and secondary liver cancer have shown that RFA is capable of generating tumor-specific antibodies as well as tumor-specific CD4 þ /CD8 þ T cells that may persist for months after treatment. Interventional Oncology in Immuno-Oncology Part 1 Slovak et al. 145
provided protection against tumoral rechallenge. 44 Another group showed that after RFA treatment, the tumoral antigen mucin 1 (MUC1) was able to stimulate T cells to release IFN-γ and increase the amount of circulating B cells. 27 Mizukoshi et al used an IFN-γ enzyme-linked immunospot assay (ELI-SPOT) assay to analyze the immune response to 11 tumorassociated antigen (TAA) peptides after RFA in HCC patients. They found that an increase in the number of TAA-specific T cells occurred in 62.3% of patients. Likewise, the increase in tumor-specific T cells was associated with protection from HCC recurrence, although this protection was not sufficient to completely prevent recurrent disease. 50 Hiroishi et al found similar results, with 80% of the HCC patients showing a significant increase in TAA-specific CD8þ T cells. They also showed that the magnitude of the specific T cell response was a significant prognosticator for protection against recurrence. 51 An additional study investigated the ability of RFA to induce a tumor-specific T cell response in patients with HCC. By assessing T cell reactivity to HCC-derived protein lysates via an IFN-γ ELISPOT, as well as via intracellular IFN-γ staining, they found that RFA significantly increased antitumor-specific T cell responsiveness, a higher frequency of circulating tumor-specific T cells, and increased expression of activation and cytotoxic surface markers. However, they also found that this immune response was not sufficient to protect against HCC recurrence. Evidence of eventual immune escape came in the form of a new HCC nodule that was not recognized by the T cells obtained at the time of ablation. 52 Other groups have specifically examined the immunological effect that RFA has on distal, untreated lesions. They have found that RFA inhibits distal lesion growth and increases the distal infiltration of neutrophils and CD4 þ T cells, but not of CD8 þ T cells.
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Microwave Ablation
Microwave ablation (MWA) is a newer form of hyperthermic ablation that differs from RFA in that it utilizes an electromagnetic field to generate heat via dipole agitation and hysteresis, instead of frictional heating via an alternating current. Unlike the current of RFA, the fields generated by MWA are able to pass through tissues with high impedance, and as such it remains effective when tissues char at temperatures above 100°. The size of MWA zones has also been shown to be less affected by local blood vessels (the heatsink effect) than RFA 55 (►Fig. 2B).
Compared with the research on RFA, relatively little work has gone into investigating the immunological effects of MWA in isolation (►Table 2). Much of the existing research has examined the effect that MWA has in combination with immunotherapy. In terms of MWA alone, the existing body of evidence seems to suggest that the immune response stimulated by MWA is substantially less than other forms of ablation. One clinical study of MWA for the treatment of HCC found that after ablation, the numbers of T cells, NK cells, and macrophages increased significantly in both the treated and untreated lesions. The same study also found a significant correlation between the level of immune cell infiltration and survival. 56 Another study that compared forms of ablation found that the levels of IL-1β and IL-6 induced after ablation were significantly less than after RFA or CA. 31 Similarly, a different study found that while MWA did induce significant expression of HSP70, the upregulation was less than RFA and CA.
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Several studies have compared the immunological effects of MWA alone versus MWA in combination with an immunotherapy. In these papers, valuable data exists on the effect that MWA monotherapy has on the immune system. For example, one study performed on murine model of breast cancer found that after MWA alone there was a significant increase in the tumoral infiltration of CD4 þ and CD8 þ T cells along with significant increases in their splenic equivalents when compared with control. The same study also identified a statistically significant increase in tumor-specific IFN-γ secreting cells as well as an increase in serum levels of IL-12 after treatment. The authors further enhanced these responses with the addition of the immunostimulant, OK-432 (Lukang Pharmaceutical, Shandong, China).
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Cryoablation CA is a unique hypothermic method of ablation; destroying cells by producing local temperatures as low as À160°C. These temperatures are achieved via the release of liquid argon gas that rapidly expands and evaporates, thereby extracting the heat out of nearby tissues and generating an ice ball. 58, 59 The alternation of argon and helium gas allows for a rapid freeze-thaw cycle. During the freezing phase, higher intracellular osmolarity initially causes ice crystals to form outside the cell. The resultant change in the osmotic gradient pulls water out of the cell, causing injury via cellular dehydration. When helium is released and the cells thaw, the osmotic gradient reverses, and water rushes back into the cells causing swelling and membrane rupture. As the influx of extracellular fluid lowers intracellular osmolarity, intracellular ice crystals may form, further damaging cellular membranes and organelles. Ice crystals can also form in the walls of nearby blood vessels and cause endothelial damage that initially increases vascular permeability and eventually leads to thrombosis. Occlusion of blood flow causes tissue ischemia that further potentiates tumor cell death 9,15,59,60 (►Fig. 2C).
There is evidence to show that CA is capable of generating both immunostimulatory and immunosuppressive effects (►Table 3). The prevailing response is believed to be dictated by the ratio of necrotic versus apoptotic cells, with a combination of the two seeming to be ideal. The cells closest to the applicator probe die by necrosis and release "danger signals" in the form of damage associated molecular proteins (DAMPs) such as DNA, RNA, and HSP. 69 Newer studies suggest that apoptotic cells themselves may be capable of releasing DAMPs and stimulating DC maturation in a process referred to as immunogenic cell death.
66,67
As an example of how the ratio of necrotic to apoptotic cells can shift the immunologic response to CA, the rate of freeze has an effect on the extent of necrosis as well as the magnitude of the immunostimulatory response induced by CA. Faster rates are associated with a significant increase in tumor-specific T cells in draining lymph nodes as well as decreased pulmonary metastases and prolonged survival when compared with slower rates. Interestingly, a low rate "Tumor-specific CD8 þ T cells [48] [49] [50] [51] [52] "Activation of myeloid DCs "HSP70 expression 34, 36 "HSP90 expression 34 Metastatic liver cancer "Tumor-specific antibodies 48 "Tumor-specific CD4 þ T cells 48, 49 "Tumor-specific CD8 þ T cells "Il-1β
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of freezing was actually associated with an increase in T reg cells and a resulting suppression of CD8 þ T cell stimulation.
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There is some data to suggest that the immune response to CA changes over time from immunosuppression to immunostimulation. In a series of papers published between 1982 and 1998, one group observed an initial increase in immunosuppression that they suggested could be due to the induction of splenic suppressor T cells (now known as T reg cells). [71] [72] [73] [74] Another group identified an increase in the population of splenic suppressor T cells (T regs ) after CA only between 1 and 10 days after treatment. 75 Using a rat model of breast adenocarcinoma, Misao et al found that while mice treated with surgical excision had a superior response to re-challenge 1 to 3 weeks after treatment, the mice that had been cryoablated experienced a significantly higher rejection rate than surgery at week 10. At this time point, only 18% of the surgically treated rats rejected the rechallenge, compared with 80% in cryoablated mice. 76 An additional study concluded that after CA there is early immunosuppression followed by increasing tumor draining lymph node cellularity and resistance to rechallenge that peaks at ten weeks. 77 It is possible that early after CA, the immunosuppressive signals from the apoptotic cells are 80 In a trial conducted on patients with primary and metastatic liver cancer, a post-CA increase in the ratio of IFN-γ to IL-4 as well as an increase in TNF-α and a decrease in IL-10 were all associated with tumor necrosis outside of the treatment area. 82 Another study that sought to investigate the prognostic ability of postablative T reg cells found that after CA, there was an overall decreased frequency of peripheral T reg cells and a reduction in the FoxP3 þ /CD8 þ T cell ratio. 83 Sabel et al used a murine model of breast cancer to demonstrate significant increases in IFN-γ and IL-12 as well as in tumor-specific T cell responses in tumor draining lymph nodes after CA. 84 Several other authors have also shown that CA confers significant resistance to rechallenge with tumoral antigens. 11,84,85 An abscopal effect has even been seen, with significant postablation protection from metastases in the liver and lungs in addition to inhibition of secondary tumor growth.
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The immune response after CA has been shown to be more substantial than after other forms of ablation. Compared with RFA or MWA, circulating levels of IL-1, IL-6, NF-κβ, and TNF-α are all significantly more elevated after CA.
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Loading of in vivo DCs with tumoral antigens is also vastly more efficient after CA than after RFA. 43 One potential explanation for the enhanced immune response after CA could be the mechanism of cell injury that it causes: hyperthermic ablative modalities like RFA and MWA destroy cellular antigens, whereas the osmotic shifts that occur with CA do not. Unlike hyperthermic techniques, the immunostimulation after CA can be so significant as to cause systemic inflammatory syndromes
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Focused Ultrasound Ablation
High-intensity focused ultrasound (HIFU) differs from other forms of thermal ablative therapies in that it is truly noninvasive. Traditionally, HIFU damages cells thermally by using the acoustic energy of several highly concentrated ultrasound beams to produce internal temperatures over BALB/c mice w/ murine breast cancer (4T1) 60°C. With the appropriate settings, HIFU can become mechanical high intensity focused ultrasound (M-HIFU) and cause nonthermal, mechanical damage via a process called acoustic cavitation. As the ultrasonic waves collide with the cells, the alterations in pressure cause gaseous nuclei within the cells to expand and contract, eventually leading to collapse of organelles and lysis of cellular membranes.
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Much like CA, HIFU has been shown to be highly immunogenic (►Table 4 the lymphocytes tend to infiltrate at the periphery of ablated lesions, one group of investigators set out to maximize the peripheral area created by HIFU treatment by using a "sparse scan" strategy that generated clusters of well-separated lesions. They found that this technique was significantly more effective at increasing DC infiltration and promoting their maturation than traditional dense scanning.
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In terms of cell-mediated immunity, a significant increase in CD4 þ cells has been associated with HIFU. 103 Several groups have documented cases where patients with solid malignancies had abnormal CD4 þ /CD8 þ ratios before treatment and then subsequently had T cell ratios normalize after "Protection vs rechallenge "DC loading 11 43 (Continued) Interventional Oncology in Immuno-Oncology Part 1 Slovak et al. 149
HIFU. 103, 104 Additional studies have shown that HIFU increases the number of cytotoxic T cells as well as the amount of IFN-γ and TNF-α secretion. 105 Protection against a tumoral rechallenge has also been proven to result from HIFU. Hu et al used a murine model of colon adenocarcinoma to show that thermal HIFU can protect against rechallenge in addition to increasing the accumulation of DCs into tumor draining lymph nodes as well as the number of tumorspecific cytotoxic T cells. 106 Another clinical study that examined the use of HIFU for the treatment of late stage pancreatic carcinoma found that while HIFU did lead to a significant increase in NK activity, the increase in CD3 þ and CD4 þ cells was non-significant. 107 One study found that in patients with various solid malignancies, HIFU decreased the circulating levels of the immunosuppressive cytokines, VEGF, TGF-β1, and TGF-β2. Notably they were able to further clarify that the levels of these cytokines were significantly lower after HIFU in patients with nonmetastatic disease as compared with those with metastases. 108 Given the range of responses seen with differing applications of HIFU, it is possible that this variation in postablative cell mediated immunity is due to variations in technique. Several investigators have looked specifically into the immune effects of M-HIFU. They found over several studies that M-HIFU induces a more robust release of danger signals, enhances DC and cytotoxic T cell function, and diminishes metastatic burden when compared with thermal HIFU. 106, 109, 110 Furthermore, when used as neoadjuvant therapy for prostate cancer, M-HIFU was found to inhibit the growth of rechallenged tumors, increase the number of cytotoxic T cells, and prolong host survival. The authors attributed the decrease in immunosuppression to a downregulation of the tumor suppressor molecule STAT3. 
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Conclusion
In situ modulation of malignant cells by thermal ablation may function as an in situ cancer vaccine, enhancing immunogenicity and promoting a tumor-specific immune response capable of exerting abscopal effects. The various forms of ablation have all shown this ability to some extent, though CA seems to be the most potent immunostimulant. Current and future studies investigating the incorporation of ablation into comprehensive immunotherapeutic regimens hold great potential for the treatment of solid tumors.
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